Lanxess Invests €40 Million in 2 Projects at Krefeld-Uerdingen Site

Laying the foundation stone (from left to right): Hubert Fink, head of the...
Laying the foundation stone (from left to right): Hubert Fink, head of the Lanxess business unit Basic Chemicals; Werner Breuers, member of the board of management of the Lanxess AG; construction manager Alexander Kerns; and Gregor Kathstede, mayor of Krefeld.

Lanxess has announced a €40 million investment in two projects at its Krefeld-Uerdingen, Germany site.The company is building a production plant for the formalin needed to make trimethylolpropane (TMP). The applications of this trivalent alcohol include numerous products used in the furniture, construction and automotive industries. In addition to the plant itself, new formalin and methanol tanks will also be built on a total area of 1,000 m2 and is due to start up at the end of 2011.

In addition, the company said it is responding to strong global demand for menthol by investing in the expansion of its existing menthol production facilities. Synthetic menthol is a key component of numerous aromas and pharmaceutical products. Lanxess - in collaboration with Symrise - is the world's leading manufacturer of synthetic menthol and thymol. Initial planning work on the expansion of the hydrogenation facility is already under way, and the project is due to be completed during the first half of 2012.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.